Compare DexCom, Inc. (DXCM) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Wells Fargo & Co — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Wells Fargo & Co trades at $82 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 7.8× DexCom, Inc.'s market cap, and Wells Fargo & Co pays a 2.44% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Wells Fargo & Co for 87 Days on average.
| DXCM | WFC | |
|---|---|---|
Market Cap | $31.86B | $248.06B |
Volume | 3,607,070 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $92.34 | $96.40 |
52-Week Low | $54.84 | $73.42 |
Typical Hold Time | 62 Days | 87 Days |
Enterprise Value | $31.32B | $503.91B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Wells Fargo (WFC) trades at $80.26, down 1.53% with a bearish technical signal. The stock shows strong fundamentals with revenue growth to $83.7B in 2025 and improving net margins to 25.49%. Recent positive developments include a credit rating upgrade to 'A-' by S&P and upcoming Q3 earnings. Valuation metrics appear attractive with P/E of 11.67 and P/B of 1.47, trading below the consensus price target of $99.13.
WFC presents a compelling value opportunity with solid profitability and analyst support (46.7% buy ratings), though near-term headwinds include recent earnings misses and bearish technical indicators. The bank's improving credit profile and stable outlook support long-term growth potential, but investors should monitor interest rate sensitivity and execution on earnings expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
